Thursday, May 27, 2021 11:33:48 AM
I, and others, have speculated that NWBO from time to time has used certain public statements to pump the share price, usually right around the time of a cash raise, to allow lenders who have been paid in warrants an opportunity to quickly cash out at a nice short-term profit. The evidence is there, like it or not. Go back and look at statements made by the Investor Relations employee and the timing of those statements, especially his comment that an upcoming ASM would be so "interesting" we wouldn't want to miss it, and he and CEO encouraging shareholders to travel to the meeting from all over the world. These comments were highly unusual and, of course, the actual meeting presentation did not bear out any of the hype, while the comments led to a substantial share price rise coincidental with a cash raise. This has happened more than once.
But those were isolated incidents. Certainly NWBO's DCVax-L Phase 3 trial, taken as a whole, is not a pump and dump scheme. That's absurd. What it is, though, is a perpetual scheme that has created impressive wealth for many of the key figures at NWBO, and especially the CEO who has made in the hundreds of millions of dollars over the lifespan of this trial (which includes my estimate of the proceeds from the sale of Cognate, which recently resold for more than $880 million).
The principals of NWBO have figured out how to make a very nice living by keeping this trial going in perpetuity. They pay themselves nicely and have all made millions and millions of dollars. Why rush Sawston? Because it's another Cognate that will lead to great wealth for the CEO regardless of whether DCVax-L is part of the production line or not. Flaskworks? That's pure cover. They paid next to nothing for that device. Maybe some years from now it will help them produce DCVax if/when it is ever approved for some limited use. Who knows? But look at what they paid for it. Doesn't that tell you anything?
NWBO is not a pump and dump, but it has been a means to a nice living for many of the key figures at NWBO. Would you deny that? And would you deny that a nice living is a sufficient incentive to keep this trial going as long as possible? It sure looks that way, because to this day they continue to refuse to release TLD, even when they said in writing they would release it last September, and then claimed they didn't lock the data until early October. That is in addition to the dozens of other times they have misled us about imminent TLD over the history of this god-forsaken trial, all well-documented. You assume that approval in other countries is a given but your reasoning is flawed. The change of endpoints on a web site has no bearing on regulatory approval, and if that were the case then what are they waiting for? Why have they been waiting for five, six, even 10 or more years? Why are they still refusing to release the data? You can't just change the endpoints at the end of a 16-year trial and think everything will be hunky dory. That's not the way scientific study works. They have major, major problems with this trial. You know it, I know it, and everyone who has ever followed a bio-tech startup knows it. Not only that, but the people running this company have lied to us over and over again. Do you still trust people even after they lie to you? Why? Why would you believe people who lie to you, don't seem to care that they've lied to you, and provide no explanation for why they lied to you? This is a sham, and it's amazing that people can't see what is happening right in front of their eyes.
Recent NWBO News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 09:10:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2024 09:24:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM